-3.37%
4.31%
-4.97%
-13.01%
-2.24%
-25.52%
24.76%
AI Spotlight on MRK
Company Description
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide.It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology.The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories.
In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications.It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG.The company was founded in 1668 and is headquartered in Darmstadt, Germany.
MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E.Merck Kommanditgesellschaft.
Market Data
| Last Price | 146.4 |
| Change Percentage | -3.37% |
| Open | 151.5 |
| Previous Close | 151.5 |
| Market Cap ( Millions) | 61456 |
| Volume | 409997 |
| Year High | 177 |
| Year Low | 136.1 |
| M A 50 | 142.02 |
| M A 200 | 155.74 |
Financial Ratios
| FCF Yield | 3.29% |
| Dividend Yield | 1.50% |
| ROE | 9.67% |
| Debt / Equity | 0.00% |
| Net Debt / EBIDTA | -54.17% |
| Price To Book | 2.25 |
| Price Earnings Ratio | 23.62 |
| Price To FCF | 30.38 |
| Price To sales | 2.93 |
| EV / EBITDA | 9.99 |
News
- Jan -31 - Merck KGaA (MKGAF) Faces 11% Stock Decline Despite AI-Driven Growth Outlook and Analyst Price Target of €200
- Jan -24 - Merck and Opentrons to automate assay kits on custom workstation
- Dec -27 - Merck KGaA's (ETR:MRK) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
- Nov -16 - Merck KGaA Third Quarter 2024 Earnings: Misses Expectations
- Nov -15 - Merck KGaA (MKGAF) Q3 2024 Earnings Call Highlights: Strong Organic Growth Amid Currency Headwinds
- Oct -17 - Merck KGaA Shares Jump on Expectations of AI Boost
- Oct -14 - Merck opens new SOD facility in South Korea
- Oct -10 - Merck unveils €290m biosafety testing facility in Maryland, US
- Oct -10 - MilliporeSigma invests $290m in biosafety facility in Maryland
- Aug -30 - Merck KGaA doses first subject in Phase III generalised Myasthenia Gravis trial
- Aug -16 - Merck KGaA (MKGAF): Morgan Stanley is Bullish on This European AI Stock Now
- Aug -03 - Merck KGaA Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line
- Aug -02 - Merck buys Mirus Bio to boost viral vector bioprocessing capacity
- Aug -01 - Health Care Roundup: Market Talk
- Aug -01 - Health Care Roundup: Market Talk
- Aug -01 - Health Care Roundup: Market Talk
- Jul -24 - Merck and GTRI to develop gene therapy for Parkinson’s disease
- Jul -08 - ASNA and Athinia® collaborate to boost semiconductor manufacturing yields through improved data sharing and traceability of subcomponent parts
- Jul -04 - Merck KGaA to advance mRNA vaccine platform with Afrigen
- Jun -25 - Health Care Roundup: Market Talk
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Life Science
Expected Growth : 4.5 %
What the company do ?
Life Science from Merck KGaA is a leading provider of products and services for researchers, pharmaceutical and biotech companies, enabling advancements in healthcare and life sciences.
Why we expect these perspectives ?
Merck KGaA's Life Science segment growth is driven by increasing demand for bioprocessing solutions, expansion in emerging markets, and strategic acquisitions. The segment benefits from the growing biopharmaceutical industry, driven by rising demand for vaccines, biosimilars, and gene therapies. Additionally, Merck's investments in digitalization and innovation enable it to capitalize on trends such as personalized medicine and precision health.
Segment n°2 -> Healthcare
Expected Growth : 5.0 %
What the company do ?
Merck KGaA's Healthcare segment offers pharmaceuticals, biopharmaceuticals, and specialty chemicals for therapeutic areas like oncology, neurology, and fertility.
Why we expect these perspectives ?
Merck KGaA's 5.0% growth in Healthcare is driven by strong demand for its pharmaceuticals, particularly in the oncology and immunology segments. The company's focus on research and development, strategic acquisitions, and expansion into emerging markets also contribute to its growth. Additionally, increasing healthcare expenditure and an aging population further support the segment's growth.
Segment n°3 -> Electronics
Expected Growth : 3.8 %
What the company do ?
Electronics from Merck KGaA is a leading provider of high-tech materials and solutions for the electronics industry, including semiconductor, display, and LED markets.
Why we expect these perspectives ?
Merck KGaA's Electronics segment growth of 3.8% is driven by increasing demand for semiconductor materials, particularly in the automotive and IoT industries. Additionally, the company's strategic investments in research and development, as well as its expanding presence in Asia, contribute to its growth momentum.
Merck Kommanditgesellschaft Auf Aktien Products
| Product Range | What is it ? |
|---|---|
| Pharmaceuticals | Merck KGaA's pharmaceutical segment offers a range of prescription medicines and vaccines for various therapeutic areas, including oncology, neurology, and immunology. |
| Life Science | Merck KGaA's life science segment provides products and services for researchers, including lab supplies, bioprocessing materials, and bioanalytical instruments. |
| Performance Materials | Merck KGaA's performance materials segment offers specialty chemicals, including pigments, liquid crystals, and other materials for various industries. |
| Allergopharma | Merck KGaA's allergopharma segment offers allergy diagnostic and treatment products, including tests and therapies for allergies. |
| Biosimilars | Merck KGaA's biosimilars segment offers lower-cost, generic versions of biologic medicines. |
| Consumer Health | Merck KGaA's consumer health segment offers over-the-counter (OTC) medicines and supplements for various health needs. |
MERCK Kommanditgesellschaft auf Aktien's Porter Forces
Threat Of Substitutes
The threat of substitutes for Merck Kommanditgesellschaft auf Aktien is moderate due to the presence of alternative pharmaceutical companies and generic drug manufacturers.
Bargaining Power Of Customers
The bargaining power of customers is low due to the specialized nature of Merck's pharmaceutical products and the lack of buyer concentration.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate due to the presence of multiple suppliers for raw materials and the company's ability to negotiate prices.
Threat Of New Entrants
The threat of new entrants is low due to the high barriers to entry in the pharmaceutical industry, including regulatory hurdles and significant capital requirements.
Intensity Of Rivalry
The intensity of rivalry is high due to the presence of established pharmaceutical companies and the ongoing competition for market share and innovation.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 26.36% |
| Debt Cost | 3.95% |
| Equity Weight | 73.64% |
| Equity Cost | 7.39% |
| WACC | 6.48% |
| Leverage | 35.79% |
MERCK Kommanditgesellschaft auf Aktien : Quality Control
MERCK Kommanditgesellschaft auf Aktien passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IPN.PA | Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors … |
| EL.PA | EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, Latin America, Asia, Oceania, and Africa. It operates in five segments: Wholesale, Retail, Lenses … |
| NOVO-B.CO | Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. … |
| HLN | Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. … |
| NOVN.SW | Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Novartis
A-Score
1-Year Total Return ->
🥈
Ipsen
A-Score
1-Year Total Return ->
🥉
EssilorLuxottica
A-Score
1-Year Total Return ->
4
Haleon
A-Score
1-Year Total Return ->
5
Merck KGaA
A-Score
1-Year Total Return ->
6
